Workers’ Compensation: 2022 Trends & Predictions
January 27, 2022
14 MIN READAs we enter 2022 still mired in the COVID-19 pandemic, the workers’ compensation industry faces another challenging year, with payers continuing to cope with staffing shortages, evolving regulatory
P&C Industry Claims Severity: Trends, Drivers and Mitigators
January 25, 2022
3 MIN READClaim severity has always been top of mind for the P&C industry.
Is the Supply Chain Creating Critical Drug Shortages?
December 29, 2021
1 MIN READWith the country well into the holiday season, issues with supply chains have made their way into pharmacies across the nation. Recently, the Food and Drug Administration (FDA) showed that there are about 111 drugs on backorder. These include medications for heart conditions, antibiotics, and cancer drugs. Currently, there are no medications on the list that represent a large volume of active prescriptions for workers’ compensation.
Release of Generic Medications for Workers' Comp in 2022
November 15, 2021
1 MIN READNext year twenty-eight drugs relevant to workers’ compensation are expected to become available as generics. These formulations will be made available once the original drug manufacturer’s brand name period of exclusivity has expired.
FDA Approves Combination NSAID/Opioid Seglentis
October 21, 2021
2 MIN READOn October 18, 2021, Seglentis was approved by the U.S. Food and Drug Administration (FDA). Seglentis contains tramadol, a short-acting opioid, and celecoxib, a non-steroidal anti-inflammatory drug (NSAID), and is indicated for adults in the management of acute pain that is severe enough to require an opioid analgesic and for which alternative treatments are inadequate.
2021 mPower Virtual Conference
On-Demand
The Mitchell | Genex | Coventry team looks forward to connecting with you at the 2021 mPower Conference, taking place virtually October 12–14, 2021.